REPL
Replimune Group, Inc.
NASDAQ · USHealthcareBiotechnology
$10.51+2.74%
Price as of Jul 20, 2026
REPL growth
Replimune Group, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -25.5%
- EBIT
- -22.0%
- EPS
- -5.3%
- Free cash flow
- -43.0%
- Operating cash flow
- -45.8%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +65.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -19.1%
- EBIT
- -22.3%
- Net income
- -26.9%
- EPS
- -10.1%
- Free cash flow
- -43.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.